MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Core Insights - MindWalk Holdings Corp. has launched B Cell Llama™, a platform aimed at discovering VHH nanobodies, which are recognized as ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies [1] Industry Overview - The sales of bispecific antibodies are projected to reach US$50 billion by 2030, indicating significant growth potential in this segment [1] - The broader cell therapy market is expected to contribute tens of billions more, highlighting the expanding opportunities within the biotechnology sector [1]